A Phase Ib/II Study of the BRAF Inhibitor Encorafenib… A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors A Phase Ib:II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E:K -mutant Solid Tumors RETOUR MarcGuevreguian2021-03-22T19:49:02+01:00
